ReviewClinics in dermatology
Epidermolysis bullosa acquisita.
Review in Clinics in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Treatment methods for oesophageal strictures in paediatric patients with epidermolysis bullosa: a systematic review.BMJ paediatrics open · 2024Pooled it
- Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.Orphanet journal of rare diseases · 2018Pooled it
- Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab.JAAD case reports · 2025Article
- Article
- Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.Journal of clinical medicine · 2023Review
- Investigation of comorbid autoimmune diseases in women with autoimmune bullous diseases: An interplay of autoimmunity and practical implications.International journal of women's dermatology · 2022Review
- Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.Journal of clinical medicine · 2022Review
- Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.American journal of clinical dermatology · 2022Review
- Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.Cells · 2022Review
- Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years.Pharmaceutics · 2022Review
- Promising Natural Products in New Drug Design, Development, and Therapy for Skin Disorders: An Overview of Scientific Evidence and Understanding Their Mechanism of Action.Drug design, development and therapy · 2022Review
- Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications.Frontiers in medicine · 2022Article
- Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.Therapeutic advances in gastroenterology · 2022Review
- Epidermolysis bullosa acquisita: an uncommon cause of esophageal stricture.Oxford medical case reports · 2021Article
- Epidermolysis Bullosa Acquisita: A Case Report.The American journal of case reports · 2020Article
- Structural and biophysical characterization of the type VII collagen vWFA2 subdomain leads to identification of two binding sites.FEBS open bio · 2020Article
- Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury.Scientific reports · 2020Article
- Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature.Cureus · 2019Article
- Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- Thyroid diseases and skin autoimmunity.Reviews in endocrine & metabolic disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Epidermolysis bullosa acquisita (EBA) is a rare, acquired, chronic subepidermal bullous disease of the skin and mucosa characterized by autoantibodies to type VII collagen (C7) structures, a major component of anchoring fibrils, which attach the epidermis to the dermis. EBA patients have tissue-bound and circulating antitype C7 autoantibodies that attack type C7 and result in a reduction or perturbation of normally functioning anchoring fibrils. Patients with EBA have skin fragility, blisters, erosions, scars, milia, and nail loss, all features reminiscent of genetic dystrophic epidermolysis bullosa. These immunoglobulin G antitype C7 antibodies are pathogenic, because when they are injected into mice, the mice develop an EBA-like blistering disease. In addition to the classical mechanobullous presentation, EBA also has several other distinct clinical syndromes similar to bullous pemphigoid, Brunsting-Perry pemphigoid, or cicatricial pemphigoid. Although treatment for EBA is often unsatisfactory, some therapeutic success has been achieved with colchicine, dapsone, plasmapheresis, photopheresis, infliximab, and intravenous immunoglobulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.